The efficacy and safety of onabotulinumtoxinA (BOTOX®, Allergan, Dublin, Ireland) in the treatment of overactive bladder syndrome (OAB) has been established in various studies and is recommended as the third-line therapy. Despite this, numerous patients who could benefit from onabotulinumtoxinA for refractory OAB are not receiving it. Patients and/or physicians have concerns and misunderstandings regarding potential post void residual (PVR).
EMJ Urology 8 [Supplement 1] . 2020
May 2020
In this issue
Latest articles
All articles![](https://www.emjreviews.com/wp-content/uploads/2024/06/Uro-Artilce-Penile-Skin-Bridge-Causing-Painful-Spontaneous-Erection-web-940x564.png)
![Contemporary Views on Performance Indicators with Audit-Feedback for Bladder Cancer Treatment](https://www.emjreviews.com/wp-content/uploads/2024/05/Contemporary-Views-on-Performance-Indicators-with-Audit-Feedback-for-Bladder-Cancer-Treatment-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2024/05/Defining-Urethral-Complications-of-Intermittent-Catheterisation-Using-Hydrophilic-Catheters-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2024/03/Ureterocutaneous-Fistula-in-Setting-of-Recurrent-Gluteal-Abscesses-Thumbnail-940x564.png)